Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study

Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study

Abstract Background Real-world data on transitioning to Immune Globulin Subcutaneous (Human) 20% solution (Ig20Gly) are limited. This study aimed to assess infusion parameters and experience of patients with primary (PID) or secondary immunodeficiencies (SID) transitioning to Ig20Gly in clinical pra...

Full description

Bibliographic Details
Main Authors: Paul K. Keith, Juthaporn Cowan, Amin Kanani, Harold Kim, Gina Lacuesta, Jason K. Lee, Jie Chen, Michelle Park, André Gladiator
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Ig20Gly
Immunoglobulin replacement therapy
Primary immunodeficiency diseases
Secondary immunodeficiency diseases
Real-world
Subcutaneous immunoglobulin
Online Access:https://doi.org/10.1186/s13223-022-00709-8

Internet

https://doi.org/10.1186/s13223-022-00709-8

Similar Items